INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $88,605 | -19.9% | 1,701 | -2.6% | 0.00% | – |
| Q2 2023 | $110,557 | +24.4% | 1,746 | +6.4% | 0.00% | – |
| Q1 2023 | $88,860 | +28.9% | 1,641 | +25.9% | 0.00% | – |
| Q4 2022 | $68,955 | +9.5% | 1,303 | -4.1% | 0.00% | – |
| Q3 2022 | $63,000 | +125.0% | 1,358 | +173.8% | 0.00% | – |
| Q2 2022 | $28,000 | +75.0% | 496 | +93.8% | 0.00% | – |
| Q1 2022 | $16,000 | +23.1% | 256 | +2.8% | 0.00% | – |
| Q4 2021 | $13,000 | +44.4% | 249 | 0.0% | 0.00% | – |
| Q3 2021 | $9,000 | -10.0% | 249 | 0.0% | 0.00% | – |
| Q2 2021 | $10,000 | +11.1% | 249 | -6.4% | 0.00% | – |
| Q1 2021 | $9,000 | +12.5% | 266 | 0.0% | 0.00% | – |
| Q4 2020 | $8,000 | +33.3% | 266 | +18.8% | 0.00% | – |
| Q3 2020 | $6,000 | -80.0% | 224 | -80.6% | 0.00% | – |
| Q2 2020 | $30,000 | +20.0% | 1,154 | -29.6% | 0.00% | – |
| Q1 2020 | $25,000 | +38.9% | 1,639 | +210.4% | 0.00% | – |
| Q4 2019 | $18,000 | +1700.0% | 528 | +256.8% | 0.00% | – |
| Q3 2019 | $1,000 | -95.7% | 148 | -91.6% | 0.00% | – |
| Q2 2019 | $23,000 | +155.6% | 1,756 | +131.7% | 0.00% | – |
| Q1 2019 | $9,000 | -47.1% | 758 | -48.4% | 0.00% | – |
| Q4 2018 | $17,000 | -71.2% | 1,468 | -45.5% | 0.00% | – |
| Q3 2018 | $59,000 | +22.9% | 2,692 | 0.0% | 0.00% | – |
| Q2 2018 | $48,000 | +29.7% | 2,692 | +56.1% | 0.00% | – |
| Q1 2018 | $37,000 | +37.0% | 1,725 | -8.0% | 0.00% | – |
| Q4 2017 | $27,000 | -12.9% | 1,876 | -3.5% | 0.00% | – |
| Q3 2017 | $31,000 | +1450.0% | 1,944 | +1925.0% | 0.00% | – |
| Q1 2017 | $2,000 | +100.0% | 96 | +47.7% | 0.00% | – |
| Q4 2016 | $1,000 | – | 65 | +109.7% | 0.00% | – |
| Q3 2016 | $0 | -100.0% | 31 | -96.2% | 0.00% | – |
| Q2 2016 | $32,000 | +113.3% | 814 | +52.1% | 0.00% | – |
| Q1 2016 | $15,000 | -59.5% | 535 | -21.3% | 0.00% | – |
| Q4 2015 | $37,000 | +15.6% | 680 | -16.0% | 0.00% | – |
| Q3 2015 | $32,000 | – | 810 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |